Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Sartorius, a prominent player in the life sciences and biopharmaceutical manufacturing sectors, is set to deepen its collaboration with NVIDIA, leveraging advanced AI technologies to accelerate the development of novel therapies. This partnership aims to integrate Sartorius' extensive expertise in life sciences with NVIDIA's cutting-edge AI-powered computing platforms and software, promising significant advancements in drug discovery and manufacturing processes.

Exploring Advanced Technologies

The collaboration will focus on utilizing NVIDIA's solutions in live-cell imaging platforms, predictive design of manufacturing processes, and more. Sartorius plans to harness NVIDIA's AI capabilities to create foundational models based on its unique data sets, develop new predictive AI models, tools, and simulations, and dialogue with regulatory authorities on using AI in life sciences.

"Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius.

A History of Collaboration

Sartorius has been collaborating with NVIDIA since 2020, integrating NVIDIA's technology into its instruments to enable edge computing applications for commercialized AI assays in the lab. The focus has been developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine. Additionally, Sartorius utilizes NVIDIA solutions for predictive bioprocess design and simulation tools for manufacturing innovative therapies.

Expanding the Partnership

The expanded collaboration will see increased adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services within the Sartorius ecosystem. This includes creating and commercializing powerful foundational models based on Sartorius' extensive data sets. New predictive AI models, tools, and simulations for various applications will be made available to Sartorius customers through the NVIDIA Clara suite and the NVIDIA DGX platform.

Future Innovations

Looking ahead, the collaboration will explore advanced technologies such as the computer-based design and simulation of complex 3D-bioprinted spheroids and organoids, as well as synthetic biological pathways and organisms designed based on Sartorius cell lines. These innovations aim to produce novel therapeutic agents and therapies, pushing the boundaries of biopharmaceutical research and development.

Plocamium Holdings can advise companies and private equity players in AI within manufacturing ecosystems at the highest level possible.

To roll out AI systems in a manufacturing environment, identify specific problems, and set clear goals. Collect and ensure data quality, then develop and integrate AI models into existing systems. Begin with pilot projects to test and refine the models, providing scalability. Train staff and manage organizational change to embrace AI. Finally, compliance with regulatory standards must be ensured, and ongoing monitoring and optimization of the AI systems must be maintained.

Case Study: Sartorius and NVIDIA Collaboration

Sartorius' collaboration with NVIDIA exemplifies how AI can be integrated into biopharmaceutical manufacturing:

Predictive Models:

Sartorius uses NVIDIA's AI solutions to develop predictive models for stem cell-derived organoids, replacing animal models in drug discovery.

Bioprocess Design:

NVIDIA Clara's suite is used for predictive bioprocess design and simulation tools, enhancing the efficiency and safety of manufacturing innovative therapies.

Foundational Models:

Sartorius plans to create and commercialize foundational AI models based on extensive data sets, making these tools available to customers through NVIDIA's platforms.

-written by James Tannahill, President of Plocamium Holdings LLC and contributor to Plocamium Global Insights.